The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast [0.03%]
EGFR突变的非小细胞肺癌患者中注射Amivantamab与Lazertinib一线治疗或与化疗二线治疗的IIb期COPERNICUS研究：视频播客
Balazs Halmos,Narjust Florez,Sarah Goldberg et al.
Balazs Halmos et al.
Introduction: In advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations (Ex19del/L858R), intravenous amivantamab is approved for first-line treatment with lazertini...
Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review [0.03%]
靶向疗法时代优化晚期胆管癌结局的机遇与方法：叙述性综述
Teresa Macarulla,Cindy Neuzillet,Gerald W Prager et al.
Teresa Macarulla et al.
Cholangiocarcinoma (CCA) represents a diverse group of malignancies. It is often identified at a late stage after the opportunity for curable resection has passed. An international educational meeting on CCA was held in Barcelona in Septemb...
Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer [0.03%]
镭-223和镥-177维铂替丁泰瑞达的序列：在转移性去势抵抗性前列腺癌中最大化系统靶向放射治疗的好处
Samuel Mehr,Ralph Hauke
Samuel Mehr
Introduction: The goals of treatment for metastatic castration-resistant prostate cancer are disease management, improving quality of life, and prolonging life. Although androgen-receptor blockade and chemotherapy can con...
The Immuno-oncology-Induced Cytokine Release Syndrome Patient Diary: A Content-Valid, Patient-Reported Outcome Measure [0.03%]
免疫抗肿瘤疗法引起的细胞因子释放综合症患者日记：一项内容有效且出自患者报告的评估指标
Edward Ted Wells,Laurence Lucats,Giovanni Abbadessa et al.
Edward Ted Wells et al.
Introduction: Cytokine release syndrome (CRS) occurs when the immune system reacts excessively to infections or certain immunotherapies, leading to a systemic inflammatory response. The clinical presentation of CRS is hig...
Abemaciclib Persistence in Patients with HR+, HER2-, Node-Positive Early Breast Cancer: a Real-World Analysis [0.03%]
ABEMACICLIB在HR阳性、HER2阴性淋巴结阳性早期乳腺癌患者中的使用持续时间：真实世界分析
Kathryn Hudson,Wambui Gathirua-Mwangi,Lindsay A Williams et al.
Kathryn Hudson et al.
Introduction: Patients with node-positive, high-risk, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) can be treated with 2 years of abemaciclib plus en...
Abemaciclib Persistence in Patients with HR+, HER2-, Node-Positive Early Breast Cancer: a Real-World Analysis [0.03%]
ABEMACICLIB在HR阳性、HER2阴性、淋巴结阳性早期乳腺癌患者中的使用持续时间：一项真实世界分析
Kathryn Hudson,Wambui Gathirua-Mwangi,Lindsay A Williams et al.
Kathryn Hudson et al.
Introduction: Patients with node-positive, high-risk, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) can be treated with 2 years of abemaciclib plus en...
Publisher Correction: Non-believer to Believer: A Podcast Conversation on the Journey from Skeptic to Proponent of Oncology Real-World Evidence [0.03%]
勘误:从怀疑者到支持者——一场关于肿瘤真实世界证据研究的播客对话
Adam Brufsky,Raymond Liu,Joanne C Ryan
Adam Brufsky
Published Erratum
Oncology and therapy. 2025 Sep 25. DOI:10.1007/s40487-025-00382-y 2025
The Role of Oncology Nurses and Advanced Practice Providers in the Treatment of Patients With HRR-Deficient mCRPC Receiving Talazoparib Plus Enzalutamide: A Podcast [0.03%]
肿瘤护士和高级实践提供者在HRD缺陷mCRPC患者接受塔拉唑帕利联合恩杂鲁胺治疗中的作用：一期临床试验播客报告
Jennifer L E Lloyd,Julia Batten
Jennifer L E Lloyd
Homologous recombination repair (HRR) is a DNA repair pathway that helps maintain genomic stability. About one quarter of patients with metastatic castration-resistant prostate cancer (mCRPC) have alterations in HRR genes. For adult patient...
Application and Progress of Antibody-Drug Conjugates (ADCs) in the Treatment of Metastatic Triple-Negative Breast Cancer [0.03%]
抗体偶联药物（ADC）在转移性三阴性乳腺癌治疗中的应用及进展
Banghong Xie,Chao Chen,Haolin Cai et al.
Banghong Xie et al.
Metastatic triple-negative breast cancer (TNBC) lacks actionable targets, and chemotherapy yields median progression-free survival (mPFS) of 4.6-9.7 months and median overall survival (mOS) of 12.6-26.3 months. Immune checkpoint inhibitors ...
First-Line Tislelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: PD-L1 ≥ 50% Subgroup Analysis from the RATIONALE-304 Trial [0.03%]
替雷利珠单抗联合化疗治疗晚期非鳞状非小细胞肺癌Ⅲ期RATIONALE 304研究PD-L1≥50%人群子集分析
Shun Lu,Jie Wang,Yan Yu et al.
Shun Lu et al.
Introduction: RATIONALE-304 compared first-line tislelizumab (a programmed cell death protein 1 inhibitor) plus chemotherapy versus chemotherapy in advanced non-squamous non-small cell lung cancer (nsq-NSCLC). This explor...